{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:48:11Z","timestamp":1791150491161,"version":"4.1.0"},"reference-count":162,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T00:00:00Z","timestamp":1362960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicinal Research Reviews"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prominent in the current stage of antiviral drug development are: (i) for human immunodeficiency virus (HIV), the use of fixed\u2010dose combinations (FDCs), the most recent example being Stribild<jats:sup>TM<\/jats:sup>; (ii) for hepatitis C virus (HCV), the pleiade of direct\u2010acting antivirals (DAAs) that should be formulated in the most appropriate combinations so as to obtain a cure of the infection; (iii)\u2013(v) new strategies (i.e., AIC316, AIC246, and FV\u2010100) for the treatment of herpesvirus infections: herpes simplex virus (HSV), cytomegalovirus (CMV), and varicella\u2010zoster virus (VZV), respectively; (vi) the role of a new tenofovir prodrug, tenofovir alafenamide (TAF) (GS\u20107340) for the treatment of HIV infections; (vii) the potential use of poxvirus inhibitors (CMX001 and ST\u2010246); (viii) the usefulness of new influenza virus inhibitors (peramivir and laninamivir octanoate); (ix) the position of the hepatitis B virus (HBV) inhibitors [lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate (TDF)]; and (x) the potential of new compounds such as FGI\u2010103, FGI\u2010104, FGI\u2010106, dUY11, and LJ\u2010001 for the treatment of filoviruses (i.e., Ebola). Whereas for HIV and HCV therapy is aimed at multiple\u2010drug combinations, for all other viruses, HSV, CMV, VZV, pox, influenza, HBV, and filoviruses, current strategies are based on the use of single compounds.<\/jats:p>","DOI":"10.1002\/med.21281","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T19:59:02Z","timestamp":1363204742000},"page":"1249-1277","source":"Crossref","is-referenced-by-count":48,"title":["A Cutting\u2010Edge View on the Current State of Antiviral Drug Development"],"prefix":"10.1002","volume":"33","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research KU Leuven  B\u20103000 Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,11]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"Gilead Sciences Press release. Available athttp:\/\/investors.gilead.com\/phoenix.zhtml?c=69964&p=irol\u2010newsArticle&ID=1728981&highlight="},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60918-0"},{"key":"e_1_2_5_4_1","first-page":"168","article-title":"Once\u2010daily single\u2010tablet regimens: A long and winding road to excellence in antiretroviral treatment","volume":"14","author":"Llibre JM","year":"2012","journal-title":"AIDS Rev"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21267"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.03.024"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/343470a0"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-12"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1727"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm201384j"},{"key":"e_1_2_5_11_1","article-title":"Structure\u2010activity relationships in the development of allosteric hepatitis C virus RNA\u2010dependent RNA polymerase inhibitors: Ten years of research","author":"Haudecoeur R","year":"2012","journal-title":"Med Res Rev"},{"key":"e_1_2_5_12_1","first-page":"1215","article-title":"Highlights in antiviral drug research: Antivirals at the horizon","volume":"33","author":"De Clercq E","year":"2013","journal-title":"Med Rev Rev"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.161802"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo201492m"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"e_1_2_5_16_1","first-page":"377A","article-title":"Once daily PSI\u20107977 plus RBV: Pegylated interferon\u2010a not required for complete rapid viral response in treatment\u2010na\u00efve patients with HCV GT2 or GT3. Abstracts of the 62th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 6\u20139 November 2011","volume":"54","author":"Gane EJ","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_5_17_1","first-page":"706A","article-title":"High rapid virologic response (RVR) with PSI\u20107977 daily dosing plus PEG\u2010INF\/RBV in a 28\u2010day phase 2a trial. Presented at the 61st Annual Meeting of the American Association of the Study of Liver Diseases, Boston, MA, October 29\u2013November 2, 2010","volume":"52","author":"Lawitz E","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_5_18_1","unstructured":"GaneE StedmanC HylandR SorensenR SymondsW HindesR BerreyM.Once daily GS\u20107977 plus ribavirin in HCV genotypes 1\u20133: The ELECTRON trial. Poster presentations of the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012 # 1113."},{"key":"e_1_2_5_19_1","unstructured":"KowdleyK LawitzE CrespoI HassaneinT DavisM DeMiccoM NelsonD BernsteinD AfdhalN JacobsonI VierlingJ GordonS AndersonJK HylandRH BakerC SorensenR HindesRG AlbanisE SymondsWT BerreyMM.GS\u20107977 + PEG\/RBV in HCV genotype 1: The ATOMIC trial. An end to response\u2010guided therapy ?Poster presentations of the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012."},{"key":"e_1_2_5_20_1","doi-asserted-by":"crossref","unstructured":"SulkowskiM GardinerD LawitzE HinestrosaF NelsonD ThuluvathP Rodriguez\u2010TorresM LokA SchwartzH ReddyKR EleyT Wind\u2010RotoloM HuangS\u2010P GaoM McPheeF HindesR SymondsB PasquinelliC GraselaD.Potent viral suppression with all\u2010oral combination of daclatasvir (NS5A inhibitor) and GS\u20107977 (NS5B inhibitor) +\/\u2010ribavirin in treatment\u2010na\u00efve patients with chronic HCV GT1 2 or 3. Poster presentations of the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012 # 1422.","DOI":"10.1016\/S0168-8278(12)61433-0"},{"key":"e_1_2_5_21_1","unstructured":"OsinusiA HeytensL LeeYJ BonD ShivakumarB. NelsonA MeissnerEG KohliA BarrettL. ProschanM. FishbeinD SilkR KwanR HerrmannE SnellerM TeferiG TalwaniR KleinerD SymondsB SubramanianM PolisM MasurH McHutchisonJ FauciAS KottililS.High efficacy of GS\u20107977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients: Interim analysis from the SPARE trial. 63rd Annual Meeting of the American Association for the Study of Liver Disease Boston MA 13 November 2012 abstract LB\u20104."},{"key":"e_1_2_5_22_1","doi-asserted-by":"crossref","unstructured":"SulkowskiM Rodriguez\u2010TorresM LawitzE ShiffmanM PolS HerringR McHutchisonJG PangPS BrainardDM WylesD HabersetzerF.High sustained virologic response rate in treatment\u2010na\u00efve HCV genotype 1a and 1b patients treated for 12 weeks with an interferon\u2010free all\u2010oral quad regimen: Interim results. Poster presentations of the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012 # 1421.","DOI":"10.1016\/S0168-8278(12)61432-9"},{"key":"e_1_2_5_23_1","doi-asserted-by":"crossref","unstructured":"SuzukiF IkedaK ToyotaJ KarinoY OhmuraT ChayamaK TakahashiS KawakamiY IshikawaH WatanabeH HuW McPheeF HughesE KumadaH.Dual oral therapy with the NS5A inhibitor daclatasvir (BMS\u2010790052) and NS3 protease inhibitor asunaprevir (BMS\u2010650032) in HCV genotype 1B\u2010infected null responders or ineligible\/intolerant to peg\u2010interferon. Oral presentations at the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012.","DOI":"10.1016\/S0168-8278(12)60028-2"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24724"},{"key":"e_1_2_5_25_1","doi-asserted-by":"crossref","unstructured":"PoordadF LawitzE KowdleyKV EversonGT FreilichB CohenD SiggelkowS HeckamanM MenonR Pilot\u2010MatiasT PodsadeckiT BernsteinB.12\u2010week interferon\u2010free regimen of ABT\u2010450\/r+ABT\u2010333+ribavirin achieved SVR12 in more than 90% of treatment\u2010na\u00efve HCV genotype\u20101\u2010infected subjects and 47% of previous non\u2010responders. Oral presentations at the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012.","DOI":"10.1016\/S0168-8278(12)61410-X"},{"key":"e_1_2_5_26_1","doi-asserted-by":"crossref","unstructured":"LawitzE PoordadF KowdleyKV JensenD CohenDE SiggelkowS WikstromK LarsenL MenonRM PodsadeckiT BernsteinB.A 12\u2010week interferon\u2010free regimen of ABT\u2010450\/r ABT\u2010072 and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment\u2010na\u00efve HCV IL28B\u2010CC genotype\u20101\u2010infected subject. Oral presentations at the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012.","DOI":"10.1016\/S0168-8278(12)60027-0"},{"key":"e_1_2_5_27_1","doi-asserted-by":"crossref","unstructured":"2012 S Zeuzem V Soriano T Asselah J\u2010P Bronowicki A Lohse B M\u00fcllhaupt M Schuchmann M Bourliere M Buti S Roberts E Gane JO Stern G Kukolj L Dai WO B\u00f6cher FJ Mensa SVR4 and SVR12 with an interferon\u2010free regimen of BI201335 and BI207127 +\/\u2010 ribavirin in treatment\u2010na\u00efve patients with chronic genotype\u20101 HCV infection: Interim results of sound\u2010C2. Oral presentations at the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) 18 22","DOI":"10.1016\/S0168-8278(12)60115-9"},{"key":"e_1_2_5_28_1","doi-asserted-by":"crossref","unstructured":"GaneEJ PockrosP ZeuzemS MarcellinP ShikhmanA BernaardsC YetzerES ShulmanN TongX N\u00e1jeraI BertassoA HammondJ StancicS.Interferon\u2010free treatment with a combination of mericitabine and danoprevir\/r with or without ribavirin in treatment\u2010na\u00efve HCV genotype 1\u2010infected patients. Poster presentations at the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012 # 1412.","DOI":"10.1016\/S0168-8278(12)61423-8"},{"key":"e_1_2_5_29_1","doi-asserted-by":"crossref","unstructured":"PenneyMS De SouzaC SeepersaudS AlvesK KozielMJ KauffmanRS Di BisceglieAM BotfieldMC on behalf of the ZENITH Study Group.All IL28B genotypes have high SVR rates in patients treated with VX\u2010222 in combination with telaprevir\/peginterferon\/ribavirin in the ZENITH study. Poster presentations at the International Liver Congress 2012\u2014The 47th Annual Meeting of the European Association for the Study of the Liver (EASL) Barcelona Spain 18\u201322April2012 # 1203.","DOI":"10.1016\/S0168-8278(12)61215-X"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24744"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.08.002"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.66.1.347"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632020801900101"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-392"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-386"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.7.2186"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.9.6979-6987.1998"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1766-1772.2002"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.11.006"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm182"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn057"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq135"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.04.008"},{"key":"e_1_2_5_44_1","unstructured":"FieldHJ MickleburghI HuangH\u2010L TileyL WaldA Ruebsamen\u2010SchaeffH ZimmermannH BirkmannA.Sensitivity of clinical isolates to helicase primase inhibitors and no detection of resistance mutations above background frequency. Abstracts of the 25th International Conference on Antiviral Research Sapporo Japan 16\u201329April 2012. Abstract no. 46."},{"key":"e_1_2_5_45_1","first-page":"17","volume-title":"No emergence of resistance under treatment with the novel HSV inhibitor AIC316 in persons with genital herpes. 51st Interscience Conference on","author":"Huang M"},{"key":"e_1_2_5_46_1","doi-asserted-by":"crossref","unstructured":"BirkmannA McCormickD KropeltD TimmlerB StoelbenS RichardMP ZimmermannH Ruebsamen\u2010SchaeffH.Excellent efficacy and pharmacokinetics have been demonstrated in pre\u2010clinical and phase I\/II studies by AIC316 a novel drug against herpes simplex (HSV) type 1 and 2. Abstracts of the 25th International Conference on Antiviral Research Sapporo Japan 16\u201329 April 2012. Abstract no. 48.","DOI":"10.1016\/j.antiviral.2011.03.014"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis019"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq198"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2011.591786"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2010.11.004"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01596-09"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.344"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.6.4721-4728.1998"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.6.757"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05265-11"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2011.10.015"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1885"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03530.x"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024334"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.10.018"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.10035"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20149"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770.2012.657383"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm000210m"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1081-1086.2005"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1661"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm376"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1472"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01446-10"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-100002496"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-100002495"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-100002338"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1898-1906.2005"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00968-06"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.045526"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01209-07"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01215-07"},{"key":"e_1_2_5_78_1","unstructured":"MarkowitzM ZolopaA RuaneP SquiresK ZhongL KearneyB LeeW.GS\u20107340 demonstrates greater declines in HIV\u20101 RNA than TDF during 14 days of monotherapy in HIV\u20101\u2010infected subjects. 18th Conference on Retroviruses and Opportunistic Infections Boston MA 27 February\u20132 March 2011. Abstract no. 152LB."},{"key":"e_1_2_5_79_1","first-page":"5","volume-title":"GS\u20107340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10\u2010day monotherapy study of HIV\u20101+ patients","author":"Ruane P"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp3002045"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.2.382-397.2001"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.02.012"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20153"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/v2102213"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02012-09"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00545-11"},{"key":"e_1_2_5_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir853"},{"key":"e_1_2_5_88_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8293"},{"key":"e_1_2_5_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/v2112409"},{"key":"e_1_2_5_90_1","first-page":"181","article-title":"Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection","volume":"13","author":"Duraffour S","year":"2010","journal-title":"IDrugs"},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00678-09"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.11.27"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00904-12"},{"key":"e_1_2_5_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023237"},{"key":"e_1_2_5_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02173-10"},{"key":"e_1_2_5_96_1","unstructured":"RussoA AgansK BraselT DearenK BaileyT ReynoldsE MoritzV StorchS BakerR.Therapeutic efficacy of ST\u2010246 in cynomolgous macaques challenged with monkeypox virus via aerosol. Abstracts of the 25th International Conference on Antiviral Research Sapporo Japan 16\u201329April 2012. Abstract no. 25."},{"key":"e_1_2_5_97_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912134107"},{"key":"e_1_2_5_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.039"},{"key":"e_1_2_5_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/v2122681"},{"key":"e_1_2_5_100_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00762-07"},{"key":"e_1_2_5_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis510"},{"key":"e_1_2_5_102_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1224305"},{"key":"e_1_2_5_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10831"},{"key":"e_1_2_5_104_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1213362"},{"key":"e_1_2_5_105_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1678"},{"key":"e_1_2_5_106_1","doi-asserted-by":"publisher","DOI":"10.2165\/11537960-000000000-00000"},{"key":"e_1_2_5_107_1","doi-asserted-by":"publisher","DOI":"10.1086\/591851"},{"key":"e_1_2_5_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2175"},{"key":"e_1_2_5_109_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0910479"},{"key":"e_1_2_5_110_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir001"},{"key":"e_1_2_5_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis352"},{"key":"e_1_2_5_112_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040261"},{"key":"e_1_2_5_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis351"},{"key":"e_1_2_5_114_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-10"},{"key":"e_1_2_5_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00412-11"},{"key":"e_1_2_5_116_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00360-11"},{"key":"e_1_2_5_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00132-11"},{"key":"e_1_2_5_118_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001079"},{"key":"e_1_2_5_119_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00753-12"},{"key":"e_1_2_5_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks150"},{"key":"e_1_2_5_121_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00333-08"},{"key":"e_1_2_5_122_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01311-09"},{"key":"e_1_2_5_123_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1688"},{"key":"e_1_2_5_124_1","doi-asserted-by":"publisher","DOI":"10.1086\/656802"},{"key":"e_1_2_5_125_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01755-09"},{"key":"e_1_2_5_126_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000786"},{"key":"e_1_2_5_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.06.017"},{"key":"e_1_2_5_128_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06456-11"},{"key":"e_1_2_5_129_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009356297"},{"key":"e_1_2_5_130_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010361914"},{"key":"e_1_2_5_131_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029778"},{"key":"e_1_2_5_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.03.001"},{"key":"e_1_2_5_133_1","doi-asserted-by":"publisher","DOI":"10.3390\/v2061279"},{"key":"e_1_2_5_134_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"e_1_2_5_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)60012-9"},{"key":"e_1_2_5_136_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.039"},{"key":"e_1_2_5_137_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332501"},{"key":"e_1_2_5_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801644"},{"key":"e_1_2_5_139_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.036"},{"key":"e_1_2_5_140_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000252061.35422.84"},{"key":"e_1_2_5_141_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02477-05"},{"key":"e_1_2_5_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21290"},{"key":"e_1_2_5_143_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22841"},{"key":"e_1_2_5_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2012.04.006"},{"key":"e_1_2_5_145_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02395-06"},{"key":"e_1_2_5_146_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f1e769"},{"key":"e_1_2_5_147_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067710"},{"key":"e_1_2_5_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.10.008"},{"key":"e_1_2_5_149_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.026"},{"key":"e_1_2_5_150_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24078"},{"key":"e_1_2_5_151_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.011"},{"key":"e_1_2_5_152_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10348"},{"key":"e_1_2_5_153_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10380"},{"key":"e_1_2_5_154_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01456-10"},{"key":"e_1_2_5_155_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01315-09"},{"key":"e_1_2_5_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.10.011"},{"issue":"1","key":"e_1_2_5_157_1","first-page":"87","article-title":"FGI\u2010104: A broad\u2010spectrum small molecule inhibitor of viral infection","volume":"5","author":"Kinch MS","year":"2009","journal-title":"Am J Transl Res"},{"key":"e_1_2_5_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.06.001"},{"key":"e_1_2_5_159_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909587107"},{"key":"e_1_2_5_160_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010026107"},{"key":"e_1_2_5_161_1","unstructured":"ColpittsCC UstinovAV KorshunVA SchangLM.The RAFIs aUY11 and dUY11 inhibit infectivity of unrelated viruses by preventing fusion of viral and cellular membranes. Abstracts of the 25th International Conference on Antiviral Research Sapporo Japan 16\u201329April 2012. Abstract no. 29."},{"key":"e_1_2_5_162_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802089200"},{"key":"e_1_2_5_163_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00941-08"}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmed.21281","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmed.21281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.21281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T07:15:30Z","timestamp":1694589330000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.21281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,11]]},"references-count":162,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1002\/med.21281"],"URL":"https:\/\/doi.org\/10.1002\/med.21281","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,11]]}}}